The article presents the discussion on completion of the first controlled clinical trial of a new treatment for tuberculosis (TB). Topics include dampening the enthusiasm generated by the mortality improvement that had been observed after 6 months of streptomycin; and despite a number of options for the treatment of both drug-sensitive and drug-resistant TB.